- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05099549
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be conducted in two phases. The Phase 1/dose escalation phase will gather preliminary safety and tolerability data for escalating doses of AFM24 in combination with SNK01 at a fixed dose in order to determine the MTD/RP2D for the combination dose regimen to be used in the Phase 2a/expansion.
The Phase 2a/expansion portion of the study will gather additional safety, tolerability, efficacy, and anti-tumor activity information for the combination of AFM24 with SNK01 in subjects with three types of advanced or metastatic EGFR-expressing cancers.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: NKGen Biotech, Inc.
- Phone Number: 9493966830
- Email: trials@nkgenbiotech.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC/Norris Comprehensive Cancer Center
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- University of Chicago
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Capable of giving signed informed consent
- Males and females age ≥ 18 years
- Phase 1/Dose Escalation : any histologically confirmed advanced or metastatic EGFR-positive malignancy for which all standard of care treatment options have been received and are no longer effective or are considered inappropriate at the discretion of the investigator.
- Phase 2a/Expansion : histologically confirmed advanced or metastatic EGFR positive malignancy of mCRC (EXP-1 cohort), SCCHN (EXP-2 cohort) or NSCLC (EXP-3 cohort).
Additional Criteria for Phase 2a/Expansion: subjects must have a disease history specific to their disease as listed below:
- EXP-1: mCRC. Metastatic colorectal cancer (mCRC) MSI low/DNA mismatch repair proficient. Subjects must have received ≥ 1 lines of previous combination therapy and must have been exposed to oxaliplatin, irinotecan, a fluoropyrimidine, a VEGF targeting agent and, if considered appropriate by the treating physician, an EGFR targeted antibody.
- EXP-2: SCCHN. Subjects with advanced or metastatic SCCHN whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease, which must have included platinum-based therapy, fluoropyrimidine, and an anti PD 1/PD-L1 antibody.
- EXP-3: NSCLC. Subjects with advanced or metastatic EGFR-expressing NSCLC (EGFR WT) whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease. Subjects must have received at least a platinum-based doublet in combination with anti-PD1/PD-L1 antibody or must have received a platinum-based doublet followed by an anti-PD1/PD-L1 antibody.
- One or more measurable tumors lesions per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate bone marrow, hepatic and renal function.
Key Exclusion Criteria:
- Superior vena cava syndrome contra-indicating hydration
- Untreated or symptomatic central nervous system (CNS) metastases
- No resolution of specific toxicities related to any prior anti-cancer therapy to Grade ≤ 1 according to the NCI-CTCAE v.5.0 (except peripheral or motor neuropathy, lymphopenia and alopecia)
- Treatment with systemic anticancer therapy or an investigational device within 4 weeks (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of the agent (if half-life is known and it is shorter) before the first dose of study treatment.
- Radiation therapy within 2 weeks before first dose of any study treatment or unresolved (NCI CTCAE v5.0 Grade > 1) toxicity from previous radiotherapy
- Clinically significant cardiovascular disease
- Major surgery within 4 weeks prior to any study treatment administration
- Any pulmonary, thyroid, renal, hepatic severe/uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol
- Active uncontrolled viral, fungal, or bacterial infection requiring systematic therapy within 14 days prior to first dose of study treatment.
- Known history of testing positive for human immunodeficiency virus (HIV), and/or positive test for Hepatitis B virus surface antigen (HBsAg) and/or positive Hep C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.
- Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring systemic immunosuppressive therapy
- A serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
- Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1, Dose Escalation
It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants. SNK01 (fixed dose) will be administered weekly by IV infusion. |
Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
Patient-specific ex-vivo expanded autologous natural killer cells.
|
Experimental: Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)
SNK01 (fixed dose) will be administered weekly by IV infusion.
|
Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
Patient-specific ex-vivo expanded autologous natural killer cells.
|
Experimental: Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)
SNK01 (fixed dose) will be administered weekly by IV infusion.
|
Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
Patient-specific ex-vivo expanded autologous natural killer cells.
|
Experimental: Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)
SNK01 (fixed dose) will be administered weekly by IV infusion.
|
Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
Patient-specific ex-vivo expanded autologous natural killer cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1/Dose Escalation
Time Frame: 28 days starting on cycle 1 day 1
|
Determine the maximum tolerated dose (MTD) of AFM24 in combination with SNK01.
To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period.
|
28 days starting on cycle 1 day 1
|
Phase 1/Dose Escalation
Time Frame: 28 days starting on cycle 1 day 1
|
Determine the recommended phase 2 dose (RP2D) of AFM24 in combination with SNK01. To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period. |
28 days starting on cycle 1 day 1
|
Phase 2a/Expansion
Time Frame: Up to 24 months
|
Determine objective response rate (ORR) of AFM24 in combination with SNK01.
Determine ORR using Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1/Dose Escalation
Time Frame: Up to 24 months
|
Assess safety and tolerability of AFM24 in combination with SNK01.
Determine frequency and severity of treatment-emergent AEs (TEAEs) per National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI CTCAE v 5.0).
|
Up to 24 months
|
Phase 1/Dose Escalation
Time Frame: Up to 24 months
|
Determine preliminary efficacy of AFM24 in combination with SNK01.
Determine ORR using RECIST v1.1 evaluated by local assessment.
|
Up to 24 months
|
Phase 1/Dose Escalation
Time Frame: 28 days starting on cycle 1 day 1
|
Maximum observed plasma concentration (Cmax) of AFM24
|
28 days starting on cycle 1 day 1
|
Phase 1/Dose Escalation
Time Frame: 28 days starting on cycle 1 day 1
|
Time to maximum plasma concentration (Tmax) of AFM24
|
28 days starting on cycle 1 day 1
|
Phase 1/Dose Escalation
Time Frame: 28 days starting on cycle 1 day 1
|
Minimum plasma concentration (Cmin) of AFM24
|
28 days starting on cycle 1 day 1
|
Phase 1/Dose Escalation
Time Frame: 28 days starting on cycle 1 day 1
|
Area under plasma concentration-time curve for dosing interval (AUCtau) of AFM24
|
28 days starting on cycle 1 day 1
|
Phase 1/Dose Escalation
Time Frame: Up to 24 months
|
Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 anti drug antibodies (ADAs) through completion of the Phase 1/dose escalation portion
|
Up to 24 months
|
Phase 2a/Expansion
Time Frame: Up to 24 months
|
Safety and tolerability of AFM24 in combination with SNK01 Frequency of TEAEs graded according to NCI CTCAE v 5.0
|
Up to 24 months
|
Phase 2a/Expansion
Time Frame: Up to 24 months
|
To assess progression-free survival (PFS) according to RECIST v1.1 by local assessment Assess the number of subjects with PFS defined as duration of time from start of combination treatment to date of progression.
|
Up to 24 months
|
Phase 2a/Expansion
Time Frame: Up to 24 months
|
To assess overall survival (OS).
|
Up to 24 months
|
Phase 2a/Expansion
Time Frame: Up to 24 months
|
To assess duration of response (DOR) according to RECIST v1.1 by local assessment.
|
Up to 24 months
|
Phase 2a/Expansion
Time Frame: Up to 24 months
|
To assess clinical benefit rate (CBR) according to RECIST v1.1 by local assessment.
|
Up to 24 months
|
Phase 2a/Expansion
Time Frame: 28 days starting on cycle 1 day 1
|
Maximum observed plasma concentration (Cmax) of AFM24.
|
28 days starting on cycle 1 day 1
|
Phase 2a/Expansion
Time Frame: 28 days starting on cycle 1 day 1
|
Time to maximum plasma concentration (Tmax) of AFM24.
|
28 days starting on cycle 1 day 1
|
Phase 2a/Expansion
Time Frame: 28 days starting on cycle 1 day 1
|
Minimum plasma concentration (Cmin) of AFM24.
|
28 days starting on cycle 1 day 1
|
Phase 2a/Expansion
Time Frame: 28 days starting on cycle 1 day 1
|
Area under plasma concentration-time curve for dosing interval (AUCtau) of AFM24.
|
28 days starting on cycle 1 day 1
|
Phase 2a/Expansion
Time Frame: Up to 24 months
|
Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 ADAs and frequency of subjects developing neutralizing ADAs.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Paul Chang, MPH, NKGen Biotech, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Head and Neck Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Lung Neoplasms
- Carcinoma, Squamous Cell
- Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Colorectal Neoplasms
- Neoplasm Metastasis
- Squamous Cell Carcinoma of Head and Neck
Other Study ID Numbers
- AFM24-SNK01-103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on AFM24
-
Affimed GmbHActive, not recruitingAdvanced Solid TumorUnited States, Korea, Republic of, Spain, Germany, United Kingdom
-
Affimed GmbHRecruitingAdvanced Solid TumorUnited States, Spain, United Kingdom, Korea, Republic of, Poland